Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

ALDER BIO Form 4 June 02, 2016	PHARMACEU'	TICALS I	INC								
FORM	Л							-	APPROVAL		
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549						N OMB Number:	3235-0287				
Check this box if no longer CTATENTED CE CHA				-					January 31,		
subject to Section 16 Form 4 or	51AIEN 5.	FEMENT OF CHANGES IN BENEFICIAL OW SECURITIES					WNERSHIP OF	Estimated burden ho	urs per		
Form 4 orresponse0.5Form 5Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,5obligationsSection 17(a) of the Public Utility Holding Company Act of 1935 or Section30(h) of the Investment Company Act of 19401(b).30(h) of the Investment Company Act of 1940								0.0			
(Print or Type R	esponses)										
1. Name and Ac DOW STEPI	2. Issuer Name and Ticker or Trading Symbol ALDER BIOPHARMACEUTICALS			5. Relationship of Reporting Person(s) to Issuer							
			INC [A		ANNAC	LUTICAL	,5 (Che	eck all applicab	le)		
(Last)	(First) (Middle)		of Earliest T Day/Year)	ransaction		X Director Officer (giv	ve title Ot	% Owner her (specify		
C/O SEVIN NOEL ROAI	ROSEN FUND D, #1670	S, 13455	05/26/2	-			below)	below)			
				4. If Amendment, Date Original Filed(Month/Day/Year)			6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person				
DALLAS, T	X 75420							More than One F			
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	ally Owned		
	2. Transaction Date Month/Day/Year)		Date, if	3. Transactio Code (Instr. 8)	Disposed (Instr. 3,	(A) or of (D) 4 and 5) (A) or		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code V		(D) Price					
Reminder: Repo	ort on a separate line	e for each cl	ass of sec	urities bene	•	•	or indirectly.	ction of	SEC 1474		
					inforr requi	nation cont red to respo ays a currer	ained in this form and unless the fo ntly valid OMB co	n are not rm	(9-02)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of 2. Derivative Co		saction Date /Day/Year)			4. Transact	5. Number iorDerivative	of 6. Date Exerci Expiration Dat		7. Title and Amount of 8 Underlying Securities I		

Edgar Filing: ALDER BIOPHARMACEUTICALS INC - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		2	Code (Instr. 8)	or Dispose (D)	Acquired (A) or Disposed of (D) (Instr. 3, 4,		Year)	(Instr. 3 and 4)		S (.
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	5
Stock Option (Right to Buy)	\$ 29.26	05/26/2016		А	15,000		<u>(1)</u>	05/25/2026	Common Stock	15,000	

Reporting Owners

Reporting Owner Name / Address				
	Director	10% Owner	Officer	Other
DOW STEPHEN M C/O SEVIN ROSEN FUNDS 13455 NOEL ROAD, #1670 DALLAS, TX 75420	Х			
Signatures				
/s/ Stephen M. Of Dow 06	5/02/2016			

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The shares subject to this option shall fully vest and become exercisable on the date of the 2017 Annual Meeting of the Stockholders of the Issuer, so long as the Reporting Person provides continuous service to the Issuer through such date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.